© 2017 Freeman & Co. LLC

The information and services provided on this website are not provided to, and may not be used by, any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any government authority or regulatory or self-regulatory organization or where Freeman & Co. or its affiliates is not authorized to provide such services or information.  Material on this website is not an offer to sell or a solicitation of an offer to buy any securities.  Transactions, products and services discussed on this website may not be appropriate for sale or use in all jurisdictions or for all investors.  The information on this website is not investment advice or other advice and should not be deemed a recommendation of any transaction or security.  Transactions described on this website are a selected sample and are not necessarily reflective of overall performance by Freeman & Co. or its affiliates.

  • Tumblr Social Icon
  • LinkedIn Social Icon
Please reload

Recent Posts

Cantor Fitzgerald’s ECM Ascent

January 22, 2018

Our investment banking clients often ask us to help identify emerging competitors – high-growth firms still small enough to sit outside the top of the league tables.  A year ago, Cantor Fitzgerald fit the bill, as an established trading and ATM player beginning to move into underwritten ECM deals.  Today, Cantor’s growing ECM clout is well-known to any bank active in the Healthcare sector.  Cantor finished 2017 as the #9 Life Sciences ECM bank, earning more underwriting fees than banks like Barclays and Credit Suisse.  Cantor has also been a key beneficiary of the continuing SPAC IPO surge.

 

Given Cantor’s top-10 position in its U.S. focus markets – Life Sciences and SPACs – can it continue its exponential growth trajectory into 2018?  Bloomberg reports that Cantor recently hired a group of more than 20 Jefferies bankers to cover the Power & Renewables space.  Cantor also brought on RBC and Goldman Sachs group heads to run Convertible Bond origination and sales.  With Healthcare IB activity booming, and expansion plans underway, Cantor should remain a growing ECM force in 2018.

 

 

Share on Facebook
Share on Twitter
Please reload

Follow Us